Using Organisms for Drug Design
Author Information
Author(s): Williams Charles H., Hong Charles C.
Primary Institution: Vanderbilt University School of Medicine
Hypothesis
A systematic development method for rational drug design can improve the drug discovery process.
Conclusion
The study suggests that using in vivo models like zebrafish and C. elegans can enhance the drug development process by addressing the limitations of traditional target-based approaches.
Supporting Evidence
- The current drug design paradigm often fails, with only 1 in 5000 discoveries making it to market.
- Zebrafish and C. elegans are highlighted as promising models for drug screening due to their genetic homology to humans.
- The study emphasizes the importance of considering ADMET properties early in the drug development process.
Takeaway
Scientists are trying to find better ways to create medicines by using tiny animals like fish and worms to test new drugs instead of just focusing on specific targets in the body.
Methodology
The article reviews various in vivo models and methodologies for drug discovery, emphasizing a systems biology approach.
Limitations
The study acknowledges that traditional drug design often fails to yield viable results and that in vivo models may have limitations in terms of anatomical and genetic similarities to humans.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website